<DOC>
	<DOCNO>NCT01990157</DOCNO>
	<brief_summary>This study two stage : Stage 1 purpose ass safety , tolerability , efficacy multiple TAB08 dose patient active Rheumatoid Arthritis methotrexate ( MTX ) treatment enough effective . Stage 2 purpose ass efficacy parameter ( ACR criterion ) least one select TAB08 dose extended patient population active Rheumatoid Arthritis methotrexate ( MTX ) treatment least 10 mg/week enough effective .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamics Efficacy Study TAB08 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Stage 1 design standard phase 1 study one arm sequential dose cohort ascend dos . Each patient dose cohort administer TAB08 several time . After last TAB08 administration patient undergo investigational-treatment-free follow-up period . At Stage 2 least one TAB08 dose , select Stage 1 study long timeframe extend patient population .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Patients must sign date inform consent prior study procedure . 2 . Male female patient age 1865 year . 3 . Rheumatoid arthritis ( RA ) diagnose 6 month 10 year ago accordance American College Rheumatology ( ACR ) diagnostic criterion rheumatoid arthritis , 1987 , ACR / European League Rheumatism ( EULAR ) , 2010 . 4 . Patients standard treatment result sufficient control symptom RA , per investigator opinion . 5 . Treatment Methotrexate least 3 month Screening visit , stable dose ≥ 10 mg weekly least 28 day first infusion study drug . Patients also treat folic acid . 6 . Active disease RA despite standard treatment : 1 . At least 6 66 joint swell least 6 68 joint painful . 2 . Level Creactive protein &gt; = 15 mg/L erythrocyte sedimentation rate &gt; = 28 mm/hour morning stiffness &gt; 45 minute . 7 . Rheumatoid factor &gt; 20 IU/mL . 8 . Adequate hematological , renal hepatic laboratory value . 9 . For men woman childbearing potential : consent use double barrier method contraception entire study period . 1 . Use diseasemodifying antirheumatic drug ( DMARDs ) except Methotrexate within 4 week treatment initiation . Use Leflunomide within 8 week first study drug infusion . Use biological immunosuppressive drug ( Adalimumab , Etanercept , Infliximab , Anakinra , Abatacept others ) 2 month first study drug administration . Use Rituximab within 12 month first study drug administration . 2 . Change Methotrexate dose within 4 week study treatment initiation . 3 . Any autoimmune disease except rheumatoid arthritis dry keratoconjunctivitis . 4 . Functional grade IV base American College Rheumatology scale . 5 . Active rheumatoid vasculitis . 6 . Any systemic disease relate joint inflammation . 7 . Pregnant breastfeed woman . 8 . Women childbearing potential refusing use effective contraceptive method entire study period . 9 . Any active infectious disease tuberculosis moment within 2 week inclusion study . 10 . Syphilis , hepatitis В , С , HIVinfection tuberculosis base result laboratory test Screening visit . 11 . Vaccination live attenuate vaccine within 6 week first study drug administration ; plan vaccination study period . 12 . Medical history recurrent clinically significant infection . 13 . Primary secondary immunodeficiency . 14 . Medical history malignant oncologic disease except excise basal cell skin cancer . 15 . Treatment glucocorticosteroids ( GKS ) dose correspond 12.5 mg/day prednisolone equivalent , change GKS dose well treatment intraarticular , i/m i/v injection GKS within 4 week first infusion study drug except topical low active GKS , GKS eardrops eyedrops/ointment , inhalant GKS stable dose entire study period . 16 . Dose change nonsteroid antiinflammatory agent within 4 week first infusion study drug . 17 . Any factor per investigator opinion might prevent patient adhere visit schedule perform study requirement . 18 . Participation clinical study experimental drug within 3 month within 5 elimination halflives ( depend whichever longer ) first infusion study drug . 19 . Medical history follow disease : myocardial infarction , angina pectoris , bronchial asthma , chronic obstructive pulmonary disease cardiovascular respiratory pathology consider serious investigator . 20 . Current uncontrolled pathology renal , endocrine , hematology central nervous system . 21 . Alcohol and/or drug abuse within 1 year first study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>